-
J. Neurol. Neurosurg. Psychiatr. · Feb 2020
Observational StudySecond IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.
- Christine Verboon, Bianca van den Berg, David R Cornblath, Esmee Venema, Kenneth C Gorson, Michael P Lunn, Hester Lingsma, Peter Van den Bergh, Thomas Harbo, Kathleen Bateman, Yann Pereon, Søren H Sindrup, Susumu Kusunoki, James Miller, Zhahirul Islam, Hans-Peter Hartung, Govindsinh Chavada, Bart C Jacobs, Hughes Richard A C RAC MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK., Pieter A van Doorn, and IGOS Consortium.
- Department of Neurology, Erasmus MC, Rotterdam, The Netherlands.
- J. Neurol. Neurosurg. Psychiatr. 2020 Feb 1; 91 (2): 113-121.
ObjectiveTo compare disease course in patients with Guillain-Barré syndrome (GBS) with a poor prognosis who were treated with one or with two intravenous immunoglobulin (IVIg) courses.MethodsFrom the International GBS Outcome Study, we selected patients whose modified Erasmus GBS Outcome Score at week 1 predicted a poor prognosis. We compared those treated with one IVIg course to those treated with two IVIg courses. The primary endpoint, the GBS disability scale at 4 weeks, was assessed with multivariable ordinal regression.ResultsOf 237 eligible patients, 199 patients received a single IVIg course. Twenty patients received an 'early' second IVIg course (1-2 weeks after start of the first IVIg course) and 18 patients a 'late' second IVIg course (2-4 weeks after start of IVIg). At baseline and 1 week, those receiving two IVIg courses were more disabled than those receiving one course. Compared with the one course group, the adjusted OR for a better GBS disability score at 4 weeks was 0.70 (95%CI 0.16 to 3.04) for the early group and 0.66 (95%CI 0.18 to 2.50) for the late group. The secondary endpoints were not in favour of a second IVIg course.ConclusionsThis observational study did not show better outcomes after a second IVIg course in GBS with poor prognosis. The study was limited by small numbers and baseline imbalances. Lack of improvement was likely an incentive to start a second IVIg course. A prospective randomised trial is needed to evaluate whether a second IVIg course improves outcome in GBS.© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.